Furthermore, previous studies reported that STAT3 inhibition and doxorubicin synergistically inhibited TNBC cells growth in vitro, reduced the expression of PD-L1 and activated immune cell-mediated cancer cell death [57], while other reports showed that SHP-2 activation enhances the activity of STING activation and chemotherapy response [74]. Here, STAT3 is linked to cancer.